Suppliers and packagers for generic pharmaceutical drug: orlistat

orlistat

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-01	60 CAPSULE in 1 BOTTLE (0135-0461-01)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-05	120 CAPSULE in 1 BOTTLE (0135-0461-05)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Haleon US Holdings LLC	0135-0461-06	170 CAPSULE in 1 BOTTLE (0135-0461-06)	2007-02-07
Haleon Us Holdings	ALLI	orlistat	CAPSULE;ORAL	021887	NDA	Aphena Pharma Solutions - Tennessee, LLC	71610-805-34	2280 CAPSULE in 1 BOTTLE (71610-805-34)	2007-02-07
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766	NDA	H2-Pharma LLC	61269-460-90	90 CAPSULE in 1 BOTTLE, PLASTIC (61269-460-90)	2010-12-17
Cheplapharm	XENICAL	orlistat	CAPSULE;ORAL	020766	NDA AUTHORIZED GENERIC	H2-Pharma LLC	61269-565-90	90 CAPSULE in 1 BOTTLE, PLASTIC (61269-565-90)	2022-06-01

Orlistat API Suppliers: Market Landscape and Supply Chain Analysis

Last updated: February 19, 2026

This report details the global supplier landscape for Orlistat, the active pharmaceutical ingredient (API) used in weight-management medications such as Xenical and Alli. It identifies key manufacturers, assesses production capacities, and examines regulatory compliance and intellectual property considerations impacting the supply chain.

Who are the Primary Manufacturers of Orlistat API?

The production of Orlistat API is concentrated among a limited number of manufacturers, primarily located in China and India. These companies leverage cost-effective manufacturing infrastructure and established expertise in complex organic synthesis. Key players include:

• China:
  • Qilu Pharmaceutical: A major Chinese pharmaceutical group with significant API production capabilities.
  • Nanjing Pharmaceuticals: A well-established entity involved in API manufacturing and distribution.
  • Zhejiang NHU Company: Known for its broad portfolio of APIs, including those for metabolic and cardiovascular conditions.
• India:
  • Dr. Reddy's Laboratories: A leading Indian multinational pharmaceutical company with a strong API division.
  • Sun Pharmaceutical Industries: One of the largest generic pharmaceutical companies globally, with extensive API manufacturing operations.
  • Laurus Labs: A rapidly growing API manufacturer with a focus on complex molecules.

These manufacturers typically operate large-scale production facilities, adhering to Good Manufacturing Practices (GMP) standards to ensure product quality and regulatory compliance. Their capacity is sufficient to meet global demand for both prescription and over-the-counter (OTC) formulations of Orlistat.

What are the Production Capacities and Scale of Operations?

Estimating precise production capacities for individual API manufacturers is challenging due to proprietary data. However, industry analysis suggests that the collective capacity of these key suppliers can produce hundreds of metric tons of Orlistat API annually.

• Batch Sizes: Production is typically carried out in multi-ton batches to optimize economies of scale.
• Facility Specifications: Manufacturing sites are equipped with advanced chemical reactors, purification systems, and quality control laboratories. Facilities often range from 50,000 to over 100,000 square feet dedicated to API synthesis and processing.
• Throughput: High-volume production lines are designed for continuous or semi-continuous operation to maximize output and minimize lead times.

The scalability of these operations allows manufacturers to respond to fluctuations in market demand, driven by factors such as the introduction of new generic products or changes in consumer health trends.

What are the Regulatory and Quality Standards for Orlistat API Production?

Orlistat API manufacturers must adhere to stringent regulatory requirements to ensure product safety, efficacy, and quality. Compliance is essential for market access in major pharmaceutical markets.

• Good Manufacturing Practices (GMP): This is the foundational standard. Manufacturers are inspected and certified by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and national agencies in India and China. Key GMP aspects include:
  • Process Validation: Ensuring that manufacturing processes consistently produce API meeting predefined specifications.
  • Quality Control: Rigorous testing of raw materials, in-process samples, and finished API for purity, potency, and impurity profiles.
  • Documentation: Comprehensive record-keeping of all manufacturing and quality assurance activities.
  • Facility and Equipment Qualification: Ensuring that manufacturing environments and equipment are suitable for intended use and maintained appropriately.
• Drug Master Files (DMFs): API manufacturers submit DMFs to regulatory authorities. These confidential documents detail the chemistry, manufacturing, and controls (CMC) of the API. Pharmaceutical companies using the API reference these DMFs in their drug product applications (e.g., New Drug Applications or Abbreviated New Drug Applications).
  • FDA DMFs: Over 20 active DMFs for Orlistat are listed in the FDA's system, indicating a robust regulatory submission history.
  • CEP/COS (Certificate of Suitability to the Monographs of the European Pharmacopoeia): Manufacturers seeking to supply to the European market often obtain CEPs, which confirm compliance with European Pharmacopoeia standards.
• Pharmacopoeial Standards: Orlistat API must meet specifications outlined in major pharmacopoeias, including:
  • United States Pharmacopeia (USP)
  • European Pharmacopoeia (Ph. Eur.)
  • Japanese Pharmacopoeia (JP)
  • Indian Pharmacopoeia (IP) These monographs define acceptable limits for assay, impurities, degradation products, residual solvents, and physical characteristics.

What is the Intellectual Property Landscape for Orlistat?

The primary composition of matter patent for Orlistat expired many years ago, leading to significant generic competition. However, intellectual property considerations continue to influence the market.

• Composition of Matter Patent: Originally held by Hoffmann-La Roche for Xenical, this patent has long expired, enabling the widespread production of generic Orlistat.
• Formulation Patents: While the API itself is off-patent, companies may hold patents on specific formulations, delivery systems, or methods of use that could impact market entry for novel Orlistat-based products.
• Process Patents: Manufacturers may develop and patent improved or novel synthetic routes for Orlistat production. These patents can offer a competitive advantage by enhancing efficiency, reducing costs, or improving impurity profiles. Patent searches reveal numerous patents related to Orlistat synthesis, purification, and polymorphic forms.
• Generic Drug Approvals: The landscape is characterized by a large number of generic drug approvals, particularly in markets like the U.S. and Europe, for both prescription and OTC strengths. For example, the FDA has approved numerous generic Orlistat 120 mg and 60 mg products.

The absence of strong composition of matter patent protection means that competition is primarily driven by manufacturing cost, quality, regulatory compliance, and the ability to secure reliable supply chains.

How is the Orlistat Supply Chain Structured?

The Orlistat supply chain involves several key stages, from raw material sourcing to final product distribution.

1. Raw Material Sourcing:
   • Precursors and key intermediates for Orlistat synthesis are sourced from chemical manufacturers. These can include basic chemicals and specialized organic compounds.
   • Reliability and quality of raw material suppliers are critical to consistent API production.
2. API Manufacturing:
   • Synthesized by specialized API manufacturers, predominantly in China and India.
   • This stage involves complex multi-step organic synthesis, purification, and drying.
3. Quality Control and Release:
   • Rigorous testing is performed on the API batch by the manufacturer to ensure it meets pharmacopoeial standards and customer specifications.
   • A Certificate of Analysis (CoA) is issued for each batch.
4. Distribution and Logistics:
   • API is shipped to pharmaceutical formulation companies globally.
   • Specialized logistics providers often handle temperature-controlled transport and customs clearance.
5. Pharmaceutical Formulation:
   • Formulation companies incorporate the Orlistat API into finished dosage forms (e.g., capsules, tablets).
   • This stage also involves extensive quality control and regulatory filings for the finished drug product.
6. Packaging and Marketing:
   • Finished products are packaged and distributed to wholesalers, pharmacies, and healthcare providers.

The global nature of this supply chain presents potential risks, including geopolitical instability, trade policy changes, and shipping disruptions. Companies often seek to diversify their supplier base to mitigate these risks.

What are the Key Challenges and Opportunities in the Orlistat Market?

The Orlistat market, like many generic API markets, faces specific challenges and presents distinct opportunities.

Challenges:

• Price Pressure: Intense competition among generic manufacturers and API suppliers leads to significant price pressure, impacting profit margins.
• Regulatory Scrutiny: Continuous evolution of regulatory requirements and increased enforcement activities necessitate ongoing investment in quality systems and compliance.
• Supply Chain Volatility: Global supply chain disruptions, raw material price fluctuations, and geopolitical events can impact availability and cost.
• Impurity Control: Maintaining stringent control over process-related impurities and potential genotoxic impurities is critical and requires advanced analytical capabilities.
• Environmental Regulations: Increasingly stringent environmental regulations in major manufacturing hubs can lead to higher operating costs and necessitate investment in waste management and pollution control technologies.

Opportunities:

• Emerging Markets: Growing demand for weight management solutions in emerging economies presents significant market expansion opportunities.
• Improved Manufacturing Processes: Development of more efficient, cost-effective, and environmentally friendly synthesis routes can provide a competitive edge.
• Strategic Partnerships: Collaboration between API manufacturers and formulation companies can lead to streamlined product development and market entry.
• Vertical Integration: Companies with capabilities in both API manufacturing and finished dosage form production can achieve greater control over their supply chain and margins.
• Specialized Formulations: While Orlistat itself is well-established, innovation in drug delivery or combination therapies incorporating Orlistat could create new market niches.

Key Takeaways

• Orlistat API production is dominated by a few large-scale manufacturers in China and India, possessing significant production capacity and adhering to global GMP standards.
• Regulatory compliance, evidenced by numerous DMFs and adherence to pharmacopoeial standards, is a critical differentiator for suppliers.
• The expired composition of matter patent for Orlistat has fostered a highly competitive generic market, with competition centered on cost, quality, and supply chain reliability.
• The global supply chain, while robust, is susceptible to various risks, necessitating strategic supplier diversification and robust logistics management.
• Opportunities exist in emerging markets, process innovation, and strategic partnerships, despite persistent price pressures and regulatory challenges.

Frequently Asked Questions

What is the typical lead time for Orlistat API orders?

Lead times can vary depending on the supplier's current production schedule, order volume, and shipping destination, but generally range from 6 to 12 weeks from order confirmation to delivery.

How does the purity of Orlistat API affect its suitability for different markets?

API purity is critical for regulatory approval in all major markets. Different pharmacopoeias (USP, Ph. Eur., JP) have specific impurity limits. Suppliers must demonstrate consistent purity levels, typically >99.0%, meeting the most stringent of these pharmacopoeial requirements to ensure broad market access.

Are there any significant geopolitical risks associated with Orlistat API supply?

Yes, geopolitical tensions, trade disputes, or export restrictions in key manufacturing regions like China and India could disrupt supply chains, impacting availability and pricing. Diversification of sourcing is a common risk mitigation strategy.

What is the role of a Certificate of Analysis (CoA) in the Orlistat supply chain?

The CoA is a crucial document accompanying each batch of Orlistat API. It verifies that the batch has undergone specified testing and meets all defined quality parameters, including assay, purity, impurity profile, and physical characteristics, as per the agreed specifications and pharmacopoeial standards.

Can Orlistat API be stored at room temperature, or does it require special conditions?

Orlistat API is typically stable when stored under controlled room temperature conditions, protected from light and moisture. Manufacturers provide specific storage recommendations on their product documentation and Certificates of Analysis, generally advising storage between 15°C and 25°C.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from https://www.fda.gov/drugs/drug-master-files-dmfs/drug-master-files-dmfs [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability (CEP). Retrieved from https://www.edqm.eu/en/certificates-suitability-cep [3] United States Pharmacopeia. (n.d.). United States Pharmacopeia and The National Formulary. [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. [5] The Indian Pharmacopoeia Commission. (n.d.). Indian Pharmacopoeia.